HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the third quarter and nine months ended December 31, 2016 under International Financial Reporting Standards (IFRS).
Q3 FY17: Key Highlights
Revenues at Rs. 37.1 billion: QoQ growth: 3%
YoY decline: 7%
Gross Profit Margin at 59.1%.
Research & Development (R&D) spend at Rs. 5.0 billion. [13.4% of Revenues]
Selling, general & administrative (SG&A) expenses at Rs. 11.3 billion [YoY decline: 6%]
EBITDA at Rs. 8.8 billion [23.7% of Revenues]
Profit after tax at Rs. 4.7 billion [12.7% of Revenues]
Q3 FY17: Key Highlights
Revenues at Rs. 37.1 billion: QoQ growth: 3%
YoY decline: 7%
Gross Profit Margin at 59.1%.
Research & Development (R&D) spend at Rs. 5.0 billion. [13.4% of Revenues]
Selling, general & administrative (SG&A) expenses at Rs. 11.3 billion [YoY decline: 6%]
EBITDA at Rs. 8.8 billion [23.7% of Revenues]
Profit after tax at Rs. 4.7 billion [12.7% of Revenues]
